The unpublished Health Service Executive (HSE) proposal suggests that prescribing Paxlovid is now deemed to have little benefit in treating Covid-19, especially with changing conditions and improved vaccine coverage.
Once considered a pivotal treatment for high-risk Covid-19 patients, Paxlovid's effectiveness is now questioned, reflecting the evolving landscape of pandemic response and the availability of other therapeutic options.
Collection
[
|
...
]